Pacific Biosciences Of California, Inc.

Pacific Biosciences of California, Inc. is a for-profit biotechnology manufacturer specializing in advanced DNA and RNA sequencing technologies and associated consumables. The company, headquartered in Menlo Park, California, has established itself as a critical supplier of next-generation sequencing solutions to the federal government across multiple civilian agencies. Pacific Biosciences produces high-throughput, long-read sequencing systems including its proprietary Sequel, Sequel II, Sequel IIe, Revio, and Vega platforms, along with comprehensive reagent kits, SMRT cells, template preparation supplies, and related laboratory consumables. Through its extensive federal contracting relationships, the company provides cutting-edge genomic sequencing capabilities that enable advanced research in agricultural genetics, infectious disease analysis, biotechnology development, and regulatory science across the U.S. government.

Pacific Biosciences has delivered a diverse portfolio of goods and services through federal prime and sub-contract awards totaling tens of millions of dollars. Prime contract deliverables include complete sequencing instrument systems such as the Revio and Vega platforms, with ceiling values reaching $1.8 million for major equipment procurements. The company supplies specialized consumables critical to sequencing operations, including SMRT cell trays, Revio reagent kits (24-packs), Sequel II sequencing kits, template preparation solutions, binding kits, and magnetic beads, with individual delivery order values ranging from under $10,000 to over $200,000. Service contracts represent another major category of federal work, encompassing comprehensive system maintenance agreements, preventive maintenance support, spare parts and labor, remote technical support, and repair services typically valued between $35,000 and $314,960 annually. Funding agencies have included the U.S. Department of Agriculture Agricultural Research Service, Food and Drug Administration, National Institutes of Health institutes (including the National Human Genome Research Institute, National Institute of Child Health and Human Development, National Institute of Allergy and Infectious Diseases, and National Heart Lung and Blood Institute), Centers for Disease Control and Prevention, National Institute on Aging, National Institute on Deafness and Other Communication Disorders, National Cancer Institute, Department of the Navy Bureau of Medicine and Surgery, and the National Institute of Allergy and Infectious Diseases. Contract types have predominantly been firm fixed-price delivery orders and purchase orders, with multiple awards designated as total small business set-asides, particularly through FDA procurements. Pacific Biosciences has also served as a sub-contractor to Leidos Biomedical Research Inc. for high-throughput sequencing instrument purchases and system installations.

Pacific Biosciences currently holds two significant single-award Indefinite Delivery Indefinite Quantity (IDIQ) contracts that serve as primary vehicles for federal procurement of its sequencing technologies. The primary IDIQ, valued at $13.5 million with the USDA Agricultural Research Service, was awarded July 1, 2021 and extends through June 30, 2026, providing the agency with flexible access to Sequel and Sequel II product family specialized scientific equipment, reagents, and services across multiple geographic locations and research initiatives. Under this USDA IDIQ, the agency has issued numerous delivery orders for sequencing instruments, reagent kits, SMRT cell trays, service contracts, and consumables to support agricultural genomics research at facilities in the Southeast, Pacific West, Plains, and Northeast regions. The secondary IDIQ, valued at $1 million with the Food and Drug Administration, was awarded March 31, 2021 and originally extended through March 2025, providing sequencing reagents, kits, and consumables to support the agency's genomic research, regulatory review activities, and food safety initiatives. Under the FDA IDIQ, the agency has issued multiple delivery orders for template preparation kits, binding reagents, SMRT cells, sequencing supplies, and specialized consumables used with Pacific Biosciences' Sequel and Sequel II platforms at facilities including the National Center for Toxicological Research and Centers for Food Safety and Applied Nutrition. Beyond these primary IDIQs, Pacific Biosciences has received direct purchase orders and delivery orders from NIH institutes and other federal agencies for equipment systems, reagent bundles, and service contracts, demonstrating the broad-based recognition of the company's technological capabilities across the federal research enterprise.